Interview with President and Director of BioCorRx, Brady Granier

BioCorRx is a biopharmaceutical company based in Anaheim, California, specializing in developing treatments for substance use disorder.  BioCorRx’s drug candidate, BICX104, is a subcutaneous solid depot pellet of a therapeutic candidate for the treatment of opioid and alcohol use disorders. Being developed to address the very common issue of patient non-compliance with adherence to daily or monthly administration of other drug withdrawal therapy products. BioCorRx is also evaluating several other products in the addiction and pain management space. It is focusing on the development and regulatory approval of medications utilizing 505(b)(2) pathway and/or in the addiction treatment industry.